Problems with the randomized discontinuation design.

Suppr

超能文献

作者信息

Sonpavde Guru, Hutson Thomas E, Galsky Matthew D, Berry William R

出版信息

J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026.

DOI:10.1200/JCO.2006.08.1026

PMID:17008711

Abstract

摘要

相似文献

Problems with the randomized discontinuation design.

J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026.

Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.

J Clin Oncol. 2008 Jul 10;26(20):3469-71; author reply 2471. doi: 10.1200/JCO.2008.17.7410.

Targeting renal cell carcinoma.

J Clin Oncol. 2009 Jul 10;27(20):3274-6. doi: 10.1200/JCO.2009.21.8461. Epub 2009 May 18.

Biomarkers in renal cell carcinoma: what next?

Curr Oncol Rep. 2011 Apr;13(2):87-9. doi: 10.1007/s11912-011-0155-2.

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.

Two new drugs for renal cell carcinoma.

Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20.

[Metastasized renal cell carcinoma - research subjects needed!].

Aktuelle Urol. 2014 Mar;45(2):99. doi: 10.1055/s-0034-1373689. Epub 2014 Apr 3.

Where does the combination of sorafenib and interferon in renal cell carcinoma stand?

Cancer. 2010 Jan 1;116(1):4-7. doi: 10.1002/cncr.24688.

ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

Cancer Treat Rev. 2007 Jun;33(4):381-90. doi: 10.1016/j.ctrv.2007.01.002. Epub 2007 Mar 23.

[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

Nihon Jinzo Gakkai Shi. 2012;54(5):574-80.

引用本文的文献

Fool's gold, lost treasures, and the randomized clinical trial.

BMC Cancer. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Problems with the randomized discontinuation design.

J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026.

Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.

J Clin Oncol. 2008 Jul 10;26(20):3469-71; author reply 2471. doi: 10.1200/JCO.2008.17.7410.

Targeting renal cell carcinoma.

J Clin Oncol. 2009 Jul 10;27(20):3274-6. doi: 10.1200/JCO.2009.21.8461. Epub 2009 May 18.

Biomarkers in renal cell carcinoma: what next?

Curr Oncol Rep. 2011 Apr;13(2):87-9. doi: 10.1007/s11912-011-0155-2.

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.

Two new drugs for renal cell carcinoma.

Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20.

[Metastasized renal cell carcinoma - research subjects needed!].

Aktuelle Urol. 2014 Mar;45(2):99. doi: 10.1055/s-0034-1373689. Epub 2014 Apr 3.

Where does the combination of sorafenib and interferon in renal cell carcinoma stand?

Cancer. 2010 Jan 1;116(1):4-7. doi: 10.1002/cncr.24688.

ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

Cancer Treat Rev. 2007 Jun;33(4):381-90. doi: 10.1016/j.ctrv.2007.01.002. Epub 2007 Mar 23.

[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

Nihon Jinzo Gakkai Shi. 2012;54(5):574-80.

引用本文的文献

Fool's gold, lost treasures, and the randomized clinical trial.

BMC Cancer. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193.